Nephros, Inc. (NEPH)
NASDAQ: NEPH · IEX Real-Time Price · USD
2.330
+0.020 (0.87%)
May 2, 2024, 3:59 PM EDT - Market closed
Nephros Revenue
In the year 2023, Nephros had annual revenue of $14.24M with 42.74% growth. Revenue in the quarter ending December 31, 2023 was $3.25M with 27.21% year-over-year growth.
Revenue (ttm)
$14.24M
Revenue Growth
+42.74%
P/S Ratio
1.72
Revenue / Employee
$459,290
Employees
31
Market Cap
24.57M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14.24M | 4.26M | 42.74% |
Dec 31, 2022 | 9.98M | -242.00K | -2.37% |
Dec 31, 2021 | 10.22M | 1.66M | 19.34% |
Dec 31, 2020 | 8.56M | -1.77M | -17.16% |
Dec 31, 2019 | 10.33M | 4.65M | 81.71% |
Dec 31, 2018 | 5.69M | 1.88M | 49.30% |
Dec 31, 2017 | 3.81M | 1.49M | 64.18% |
Dec 31, 2016 | 2.32M | 376.00K | 19.34% |
Dec 31, 2015 | 1.94M | 196.00K | 11.21% |
Dec 31, 2014 | 1.75M | 8.00K | 0.46% |
Dec 31, 2013 | 1.74M | -67.00K | -3.71% |
Dec 31, 2012 | 1.81M | -407.00K | -18.38% |
Dec 31, 2011 | 2.21M | -724.00K | -24.64% |
Dec 31, 2010 | 2.94M | 277.00K | 10.41% |
Dec 31, 2009 | 2.66M | 1.19M | 80.65% |
Dec 31, 2008 | 1.47M | 277.00K | 23.16% |
Dec 31, 2007 | 1.20M | 402.00K | 50.63% |
Dec 31, 2006 | 794.00K | -1.63M | -67.25% |
Dec 31, 2005 | 2.42M | 2.29M | 1,651.72% |
Dec 31, 2004 | 138.41K | - | - |
Dec 31, 2003 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Exagen | 52.55M |
Cumberland Pharmaceuticals | 39.55M |
Ekso Bionics Holdings | 18.28M |
Addex Therapeutics | 1.96M |
Oncternal Therapeutics | 785.00K |
Bullfrog AI | 65.00K |
Biora Therapeutics | 4.00K |
NEPH News
- 7 weeks ago - Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results - GlobeNewsWire
- 6 months ago - Nephros Announces Results for Quarter Ended September 30, 2023 - GlobeNewsWire
- 6 months ago - Nephros Hires Judy Krandel as Chief Financial Officer - GlobeNewsWire
- 6 months ago - Nephros Schedules Third Quarter 2023 Financial Results Conference Call - GlobeNewsWire
- 8 months ago - Nephros to Present at LD Micro Main Event XVI - Newsfile Corp
- 9 months ago - Nephros Announces Results for Quarter Ended June 30, 2023 - GlobeNewsWire
- 10 months ago - Nephros Schedules Second Quarter 2023 Financial Results Conference Call - GlobeNewsWire